Fast Track Initiative

Fast Track Initiative (FTI) is a leading life science venture capital firm investing in early-stage and newco creations with a strong focus on biotechnology and healthcare. It provides hands-on operational support to its 30+ portfolio companies across therapeutics, diagnostics, digital health, and healthcare services. FTI leverages deep industry networks in Japan and the US to help startups grow from seed to commercialization. Its portfolio includes companies developing small molecules modulating RNA modification enzymes for cancer and other diseases; monoclonal antibody platforms for oncology; regenerative medicine technologies; precision cancer vaccines; cell therapy platforms for autoimmune disease; medical device software for cerebral aneurysm analysis; among others.

FTI has co-led major funding rounds such as RegCell’s $45.8M round for Treg cell therapy development. It also participated in STORM Therapeutics’ Series B financing supporting first-in-class RNA methyltransferase inhibitors entering clinical trials.

The company manages over $200 million AUM and operates from offices in Cambridge/Boston (USA) and Tokyo (Japan).

FTI does not develop drugs or devices itself but enables innovation through investment.

Portfolio highlights include: - RegCell – Treg cell therapy platform for autoimmune diseases. - STORM Therapeutics – Small molecule METTL3 inhibitor targeting RNA methyltransferases in oncology. - Braizon Therapeutics – Nano-micelle drug delivery system crossing the blood-brain barrier. - Chiome Bioscience – Monoclonal antibody discovery/development. - CellSeed – Regenerative medicine/cell sheet engineering products.

See [1] for more details on portfolio companies.